AI Article Synopsis
- The study aimed to identify and analyze hematopoietic adverse drug reactions (ADRs) linked to four PARP inhibitors: Olaparib, Niraparib, Rucaparib, and Talazoparib, using data from the FDA's FAERS database.
- Methodology involved data extraction from 2019 to 2024, applying standardized medical terminology to screen ADR signals using various statistical methods.
- Results showed that hematopoietic reactions mainly occurred within 30 days of treatment, with Niraparib presenting the highest adverse events, indicating the need for careful monitoring and individualized treatment plans for patient safety.
Article Abstract
Objectives: Analyze hematopoietic ADR signals of PARP inhibitors (Olaparib, Niraparib, Rucaparib, Talazoparib) using FAERS data to inform clinical practice.
Methods: Extracted ASCII data for these drugs from Q1 2019 to Q2 2024. Employed SMQ and PT for standardization. Screened ADR signals via ROR, PRR, and MHRA method, comparing SMQ ratios.
Results: Hematopoietic ADRs peaked within 30 days post-treatment, with cytopenia and leukopenia most prevalent. Niraparib showed the highest adverse event count and signal intensity. Olaparib and Talazoparib also indicated strong hematotoxicity.
Conclusion: PARP inhibitors vary in ADR incidence and duration, necessitating personalized treatment plans for optimized safety and rational use.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/14740338.2024.2443781 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!